Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN) Apr 10, 2024 04:02PM
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences Apr 10, 2024 04:01PM
Alpine Immune Sciences (ALPN) Presents New Preclinical Data on Povetacicept in Myasthenia Gravis Nov 3, 2023 09:01AM
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting Nov 3, 2023 09:00AM
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023 Oct 13, 2023 09:05AM
View Older Stories

Oct 4, 2023 08:04AM Alpine Immune Sciences (ALPN) Appoints Wolfgang Dummer as Chief Medical Officer
Oct 4, 2023 08:00AM Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
Sep 12, 2023 08:30AM Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
Sep 5, 2023 04:30PM Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
Sep 5, 2023 08:30AM Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
Aug 30, 2023 04:30PM Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
Aug 22, 2023 04:31PM Alpine Immune Sciences (ALPN) Appoints Christina Yi as CTO
Aug 22, 2023 04:30PM Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
Aug 14, 2023 04:15PM Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
May 19, 2023 04:30PM Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
May 11, 2023 04:15PM Alpine Immune Sciences Reports First Quarter 2023 Financial Results
May 1, 2023 04:30PM Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
Mar 23, 2023 04:06PM Alpine Immune Sciences (ALPN) Reports Q4, Provides Corporate Update
Mar 23, 2023 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 22, 2023 08:46AM Alpine Immune (ALPN) and Truveta Partner to Accelerate Recruitment to Povetacicept Clinical Trials
Mar 22, 2023 08:45AM Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical Trials
Mar 20, 2023 04:30PM Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Mar 16, 2023 05:30PM Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Mar 15, 2023 04:30PM Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
Feb 28, 2023 04:33PM Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
Feb 9, 2023 04:45PM Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
Nov 22, 2022 04:15PM Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
Nov 14, 2022 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 7, 2022 04:30PM Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
Nov 3, 2022 04:50PM Alpine Immune Sciences (ALPN) Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data
Nov 3, 2022 04:15PM Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
Nov 3, 2022 09:00AM Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
Oct 26, 2022 04:30PM Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
Oct 24, 2022 07:30AM Alpine Immune Sciences (ALPN) Terminates Enrollment of Davoceticept NEON-1 and NEON-2 Studies
Oct 24, 2022 07:30AM Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
Sep 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Sep 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Sep 12, 2022 04:05PM Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
Sep 6, 2022 04:05PM Alpine Immune Sciences Announces Participation in September Investor Conferences
Aug 30, 2022 04:05PM Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
Aug 18, 2022 04:05PM Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
Aug 11, 2022 04:05PM Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Aug 10, 2022 05:02AM Alpine Immune Sciences (ALPN) and Evotec (EVO) Expand Partnership for Development of ALPN-303
Aug 10, 2022 01:55AM Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Aug 10, 2022 01:30AM Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Aug 4, 2022 04:05PM Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Jul 19, 2022 08:05AM Alpine Immune Sciences (ALPN) Appoints Jorn Drappa to its Board
Jul 19, 2022 08:05AM Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
Jun 7, 2022 08:06AM Alpine Immune Sciences (ALPN) Appoints Andrew S. Sandler as Chief Medical Officer
Jun 7, 2022 08:05AM Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
Jun 1, 2022 08:05AM Alpine Immune Sciences (ALPN) Provides Update on ALPN-303
Jun 1, 2022 08:05AM Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
May 26, 2022 05:30PM Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
May 24, 2022 08:05AM Alpine Immune Sciences (ALPN) Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
May 24, 2022 08:05AM Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
View Older Stories